Adagene Inc-adr (ADAG)
$2.22
Performance
- $2.21$2.41$2.22
0.45%
Downside
Day's Volatility :8.46%
Upside
8.04%
- $1.34$4.38$2.22
39.64%
Downside
52 Weeks Volatility :69.41%
Upside
49.32%
Returns
| Period | Adagene Inc-adr | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -14.29% | -8.6% | 0.0% |
6 Months | -14.62% | -3.3% | 0.0% |
1 Year | 62.04% | 9.4% | 0.0% |
3 Years | -76.11% | 6.2% | -24.5% |
Highlights
Market Capitalization | 108.5M |
Book Value | $1.28 |
Earnings Per Share (EPS) | -0.72 |
Wall Street Target Price | 10.54 |
Profit Margin | 0.0% |
Operating Margin TTM | -4534.83% |
Return On Assets TTM | -19.59% |
Return On Equity TTM | -45.7% |
Revenue TTM | 815.7K |
Revenue Per Share TTM | 0.02 |
Quarterly Revenue Growth YOY | -84.8% |
Gross Profit TTM | 10.2M |
EBITDA | -36.1M |
Diluted Eps TTM | -0.72 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | -0.69 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 374.77%
Technicals Summary
Sell
Neutral
Buy
Adagene Inc-adr is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Adagene Inc-adr | -17.78% | -14.62% | 62.04% | -76.11% | -84.34% |
 Regeneron Pharmaceuticals, Inc. | -23.12% | -24.58% | -7.12% | 15.69% | 116.3% |
 Biontech Se | -4.64% | 15.06% | 7.66% | -66.93% | 422.85% |
 Alnylam Pharmaceuticals, Inc. | -19.77% | 55.93% | 41.76% | 25.27% | 116.5% |
 Vertex Pharmaceuticals Incorporated | -6.29% | 0.48% | 25.55% | 146.84% | 108.31% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Adagene Inc-adr | NA | NA | NA | 0.0 | -0.46 | -0.2 | NA | 1.28 |
Regeneron Pharmaceuticals, Inc. | 18.73 | 18.73 | 1.13 | 44.87 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.02 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -0.17 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.22 | 0.51 | -0.03 | 0.12 | NA | 60.65 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Adagene Inc-adr | Buy | $108.5M | -84.34% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $83.2B | 116.3% | 18.73 | 33.61% |
Biontech Se | Buy | $23.9B | 422.85% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $30.4B | 116.5% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $120.3B | 108.31% | 32.84 | -4.51% |
Insights on Adagene Inc-adr
Decreasing Revenue
Revenue is down for the last 3 quarters, 17.29M → 407.87K (in $), with an average decrease of 48.8% per quarter
Decreasing Net Profit
Netprofit is down for the last 6 quarters, -4.10M → -8.50M (in $), with an average decrease of 19.0% per quarter
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 29.4% return, outperforming this stock by 106.7%
Institutional Holdings
Wuxi AppTec Co Ltd
9.00%Fidelity International Ltd
8.64%SC China Holding Ltd
3.03%FMR Inc
2.91%General Atlantic Llc
0.60%Morgan Stanley - Brokerage Accounts
0.42%
Company Information
adagene was co-founded by two serial entrepreneurs to power antibody discovery. its aim is to become the leading player in antibody discovery and engineering. it has developed a proprietary dynamic precision library (dpl) and is showcasing the power of the library with a unique pipeline of innovative antibody therapeutics that is advancing into clinical trials. adagene previously has raised three series of financing with over $86 million. investors include f-prime capital (formerly fidelity biosciences), eight roads ventures china (formerly fidelity growth partners asia), 6 dimensions capital, gp healthcare capital, sequoia china, and new world tmt. for more information, please visit www.adagene.com.
Organization | Adagene Inc-adr |
Employees | 174 |
CEO | Dr. Peter P. Luo Ph.D. |
Industry | Healthcare |
Discover More
Usana Health Sciences Inc.
$2.22
-0.89%
Corbus Pharmaceuticals Holdings, Inc.
$2.22
-0.89%
Precigen Inc
$2.22
-0.89%
Patterson Companies, Inc.
$2.22
-0.89%
Bluebird Bio, Inc.
$2.22
-0.89%
Ars Pharmaceuticals Inc
$2.22
-0.89%
Dynavax Technologies Corporation
$2.22
-0.89%
Curis Inc
$2.22
-0.89%
Hookipa Pharma Inc.
$2.22
-0.89%